الصفحة الرئيسية>>Signaling Pathways>> Microbiology & Virology>> HIV>>TAK-220

TAK-220

رقم الكتالوجGC32135

TAK-220 هو مضاد CCR5 انتقائي ومتوفر حيوياً عن طريق الفم ، مع IC50s من 3.5 نانومتر و 1.4 نانومتر لتثبيط ربط RANTES و MIP-1α بـ CCR5 ، على التوالي ، لكنه لا يظهر أي تأثير على الارتباط بـ CCR1 ، CCR2b ، CCR3 ، CCR4 أو CCR7 ؛ يثبط TAK-220 أيضًا بشكل انتقائي فيروس نقص المناعة البشرية -1 ، مع EC50s لـ 1.2 نانومتر (HIV-1 KK) ، 0.72 نانومتر (HIV-1 CTV) ، 1.7 نانومتر (HIV-1 HKW) ، 1.7 نانومتر (HIV-1 HNK) ، 0.93 نانومتر (HIV-1 HTN) ، و 0.55 نانومتر (HIV-1 HHA) ، و EC90s من 12 نانومتر (HIV-1 KK) ، 5 نانومتر (HIV-1 CTV) ، 12 نانومتر (HIV-1 HKW) ، 28 نانومتر (HIV-1 HNK) ، 15 نانومتر (HIV-1 HTN) ، و 4 نانومتر (HIV-1 HHA) في PBMCs

Products are for research use only. Not for human use. We do not sell to patients.

TAK-220 التركيب الكيميائي

Cas No.: 333994-00-6

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
391٫00
متوفر
1mg
138٫00
متوفر
5mg
321٫00
متوفر
10mg
459٫00
متوفر
50mg
1379٫00
متوفر
100mg
1930٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

TAK-220 is a selective and orally bioavailable CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC90s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.

TAK-220 is a selective CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5 in CHO cells, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7. TAK-220 (0-1000 nM) interacts with CCR5 but not with RANTES and inhibits the CCR5-mediated Casup>2+ signaling. TAK-220 inhibits R5 HIV-1 (JR-FL) envelope-mediated membrane fusion, with an IC50 value of 0.42 nM, but does not alter X4 HIV-1 (HXB2) envelope-mediated membrane fusion. TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC90s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs[1]. TAK-220 shows potent inhibitory activity against the R5 isolates, with IC50s of 3.12 nM against HIV-1 R5-08, 13.47 nM against HIV-1 R5-06, and 2.26 nM against HIV-1 R5-18. TAK-220 (>100 nM) has no toxicity in uninfected PBMCs[2].

[1]. Takashima K, et al. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother. 2005 Aug;49(8):3474-82. [2]. Tremblay CL, et al. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. Antimicrob Agents Chemother. 2005 Aug;49(8):3483-5.

مراجعات

Review for TAK-220

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TAK-220

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.